Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
LUCD Lucid Diagnostics
1.270-0.030-2.31%
Trading Session
02/08 12:06 ET
High
1.310
Open
1.290
Turnover
25.46K
Low
1.270
Pre Close
1.300
Volume
19.70K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Why PAVmed Shares Are Falling Today
PAVmed Inc. (NASDAQ:PAVM) shares are trading lower after the company announced a workforce reduction of roughly 20% alongside other cost-cutting measures. What happened: PAVmed and its subsidiaries, L
TC Biopharm, G Medical Top Healthcare Gainers; Lucid, Hyperfine Among Losers
PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs
PAVmed Inc (NASDAQ:PAVM), its majority-owned subsidiaries Lucid Diagnostics Inc (NASDAQ:LUCD), and Veris Health Inc provided a strategic business update outlining near-term strategic priorities and re
Needham Keeps Their Buy Rating on Lucid Diagnostics (LUCD)
PAVmed, Its Units Lucid Diagnostics, Veris Health Implement Strategic Changes, Layoffs
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersLucid Diagnostics (NASDAQ:LUCD) shares moved upwards by 10.9% to $1.73 during Tuesday's after-market session. The market value of their outstanding shares is at $67.6 million. Nymox Pharmaceuti
PAVmed, Lucid Diagnostics Provide Business Update Highlighting Resource Reallocation; Says Implemented Workforce Reduction Of ~20%
PAVmed, Lucid Diagnostics Provide Business Update Highlighting Resource Reallocation; Says Implemented Workforce Reduction Of ~20%
PAVmed and Lucid Diagnostics Provide Strategic Business Update
PAVmed, Subsidiaries Implement Workforce Reduction of Roughly 20%
Lucid Diagnostics to Hold a Conference Call
Company Overview
More
Lucid Diagnostics, Inc. develops medical testing devices. It is a commercial-stage medical diagnostics technology company which focuses on gastroesophageal reflux disease (GERD), acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The firm's products include EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus without the need for endoscopy and EsoGuard is a laboratory developed test which analyzes methylated biomarkers. The company was founded on May 8, 2018 and is headquartered in New York, NY.
CEO： Dr. Lishan Aklog, M.D.
Market： NASDAQ
Listing Date： 10/14/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet